Hi [[ session.user.profile.firstName ]]

Medical Research

  • Extractables and leachables testing using a Quality Risk Management approach
    Extractables and leachables testing using a Quality Risk Management approach Dhaval Tapiawala, Pfizer and Satish Kumar Mohanvelu Life Sciences Management Professional at MilliporeSigma Recorded: Oct 17 2018 79 mins
    • Understanding extractables and leachables for better adoption of single use systems
    • Ensuring safety of drug through determining the level of leachables throughout product life cycle
    • Case Study of implementation of standardized testing protocol
  • Digital therapeutics and healthcare innovation
    Digital therapeutics and healthcare innovation Roberto Ascione, Healthware International, Megan Coder, Digital Therapeutics Alliance, Pierre Leurent, Voluntis Recorded: Oct 12 2018 70 mins
    Digital technology is transforming the way that healthcare is practiced and delivered, with areas like digital therapeutics forging ahead to complement traditional medical approaches and augment patient care.

    The development of software applications that are available with a prescription took a major step forward last year with the first FDA approval for a mobile medical application with both a safety and efficacy label.

    At the same time as digital therapeutics are breaking new ground there’s a whole ecosystem of digital health innovations that are also tackling healthcare issues in new and imaginative ways.

    From doctor-patient communication to managing healthcare costs, from healthcare monitoring to clinician workflow, the range of digital health tools and services available is rapidly expanding.

    We’ll be looking at how digital and traditional approaches to medicine are being combined to improve patient outcomes.

    This free webinar will also see our expert panel:
    •Consider the current state of play with digital therapeutics and what the future holds for them
    •Discuss how to harness healthcare innovations to involve and engage patients
  • Engaging with patient communities – tailoring approaches
    Engaging with patient communities – tailoring approaches Jamie Bearse, Thomas Farrington, Chuck Strand and Jenny Kite Recorded: Oct 11 2018 62 mins
    Change Together will be presenting a live webinar with leading figures from the patient advocacy community, who will discuss communication and engagement as well as the different approaches advocacy groups can take to address the unique challenges of their communities. This will be helpful for all advocates, as we hear and learn from our expert panel how their organizations are bringing about change.
  • Lighten Up!  Long-term imaging with ultra-bright, organic AIE cell trackers
    Lighten Up! Long-term imaging with ultra-bright, organic AIE cell trackers Liu Bin, PhD,Department Head - Department of Chemical and Biomolecular Engineering, National University of Singapore Recorded: Oct 10 2018 33 mins
    With the recent discovery of a special class of organic compounds with aggregation-induced emission (AIE) characteristics, new opportunities have opened for in vitro and in vivo imaging. In combination with advanced polymer encapsulation technologies, AIE compounds are now available as LuminiCell ultra-bright, organic nanoparticles that enable long-term cell tracking and imaging for applications such as cancer research and stem cell biology.
  • New Commercialization and Revenue Strategies for Medical Technology Companies
    New Commercialization and Revenue Strategies for Medical Technology Companies Charlie Whelan, Vice President of Consulting, Transformational Health, Frost & Sullivan Recorded: Oct 9 2018 61 mins
    In a market where products are increasingly commoditized and healthcare providers are being rewarded for outcomes, medical technology companies must realign their current and future business models to account for disruptive forces in the industry. Companies that have historically competed based on engineering skill and clinical evidence are finding new sources of innovation and value creation. Many medical device companies still struggle to unlock this value and find effective ways to partner with their healthcare customers. Firms that fail to capture this opportunity will fall further behind competitors who are creating revenue streams built on delivering outcomes supported by data-empowered services.
  • How Clinical Laboratories Save Money & Help Physicians Become Patient-Centric
    How Clinical Laboratories Save Money & Help Physicians Become Patient-Centric Jeffrey Reid, Tony McCraney Recorded: Oct 9 2018 30 mins
    Value-based healthcare policies continue driving the healthcare market away from a fee-for-service model and more toward an enhanced patient management model. Therefore, physicians need to become more patient-centric to strengthen their competitiveness in the marketplace.

    While this market shift continues expanding, physicians depend heavily on diagnostic testing to aid patient therapy and treatment in a timely manner. In return, the patient's chronic disease outcome may drastically improve.

    Since clinical laboratories analyze and generate the test results, they are one of the most vital pieces in this dynamic market shift. The laboratory decision makers will need to implement strategies to enhance laboratory efficiencies, keep up with the ever-growing sample volumes and counter the decline in test reimbursements.

    Join this webinar to learn…

    …the current market trends that are impacting clinical laboratories.

    …how clinical laboratories can become more competitive in the marketplace.

    …ways clinical laboratories can provide high quality test results and reduce overall operating costs via a versatile and fully automated chemistry analyzer.

    Presenters:
    Jeffrey Reid
    MedTest Dx, Director of Business Development

    Tony McCraney
    Premier Medical laboratory, Chemistry Supervisor


    **All Questions Will Be Answered After the Webinar**
  • Realising the biotech promise: addressing the path to market
    Realising the biotech promise: addressing the path to market Steve Bates, BIA, Sheela Upadhyaya, NICE, Fred Jacobs, TYG, Dean Summerfield, IQVIA Recorded: Oct 9 2018 72 mins
    Now more than ever before, Biotech is the engine for innovation in medicine, finding, creating and delivering ground-breaking treatments to patients.

    The journey from molecule discovery and development through valuation, funding, regulatory and commercialisation can be a long and complex road to travel though.

    These companies have to navigate a rapidly changing and increasingly complex landscape from pre-clinical valuation through foresight and planning at every stage of the asset life cycle - and at a time when Brexit adds uncertainty about regulatory approval and launch windows.

    Working with IQVIA, pharmaphorum has assembled a specialist panel to discuss these challenges and the most effective routes to overcoming them.

    On Tuesday 9th October at 15:00 BST / 10:00 EST we will present a free-to-attend online debate which will bring these experts together to deliver insight on topics such as market valuation, financing, navigating regulatory hurdles, patient engagement & HTA strategies through to successful commercialisation.
  • Impact of Depth Filtration on Disulfide Bond Reduction during Downstream Process
    Impact of Depth Filtration on Disulfide Bond Reduction during Downstream Process Brian O’ Mara, Senior Research Scientist I, Bristol-Myers Squibb and Alexei Voloshin, Global Application Strategy Specialist Recorded: Oct 8 2018 79 mins
    Title:Impact of Depth Filtration on Disulfide Bond Reduction during Downstream Processing of Monoclonal Antibodies from CHO Cell Cultures

    Presenters: Brian O'mara, Senior Research Scientist I, Bristol-Myers Squibb and Alexei Voloshin, Global Application Strategy Specialist
    • Understand disposable depth filtration technology used in the recovery of antibodies from CHO cell cultures as a unit operation leading to cellular lysis under particular operational conditions • Study how cellular lysis occurring during depth filtration releases endogenous REDOX regulating enzymes and co-factors into the clarified harvest, resulting in the reduction of antibody interchain disulfide bonds • Classify critical process parameters and quality attributes of the clarified harvest to be monitored during filtration development • Discuss risk mitigation strategies to control antibody reduction when using single-use disposable technologies in the recovery of antibodies from CHO cells
  • Implementing CMC Strategies for scale-up operations in biologics manufacturing
    Implementing CMC Strategies for scale-up operations in biologics manufacturing Dr Anita Krishnan, Lupinand -Dr. Annu Uppal, Global Demo Lead and Advanced Workflow Specialist at SCIEX Recorded: Oct 5 2018 73 mins
    Biotechnological products are so complex, that manufacturing biologics which are both cost-effective and with best product quality, is a technical challenge. In the context of biosimilar manufacturing at each step, the sponsor should evaluate the extent to which there is residual uncertainty about the biosimilarity of the proposed product. Often there is remnant quality difference beyond the capability of process to address. In such instances, in-depth understanding of the process, impurities, analytical methods, the mechanism of action (MOA) of the drug substance and clinical relevance of any observed structural differences, will help in implementing novel CMC strategies. This talk will examine the elements of biopharmaceutical development that lead to successful licensure of biotherapeutics.
  • A full overview of different technologies to increase HPLC efficiency & speed
    A full overview of different technologies to increase HPLC efficiency & speed Dr. Frank Michel, Analytical & Chromatography Scientific Advisor, Merck KGaA, Darmstadt, Germany Recorded: Oct 4 2018 64 mins
    In the recent decades the demand for higher separation efficiency or higher speed in HPLC has increased strongly. The response to this demand was answered by modern HPLC technologies such as UHPLC with sub-2 µm particles, monolithic silica or Fused-Core™ particles. This webinar provides an overview on the factors that influence the speed of the HPLC method. It introduces the different approaches of small HPLC particles, Fused-Core (also known as core-shell) particle technology and monolithic silica rods and discusses the advantages and disadvantages of each approach. The presentation covers the theoretical background of these technologies and multiple examples of applications.
  • Developability Assessment of Therapeutic Proteins – A Toolbox for Tackling Incre
    Developability Assessment of Therapeutic Proteins – A Toolbox for Tackling Incre Thorsten Lorenz, Team Head Developability Assessment Biologics, Novartis and Beate Kern, Product Manager, NanoTemper Recorded: Sep 27 2018 65 mins
    Title: Developability Assessment of Therapeutic Proteins – A Toolbox for Tackling Increasing Complexity
    Presenter: Thorsten Lorenz, Team Head Developability Assessment Biologics, Novartis

    Early lead selection of biotherapeutics during preclinical development requires careful characterization of a variety of molecule properties to reduce the risk for encountering unexpected obstacles during technical development. The diversity and increasing complexity of new protein formats requires a change from former platform approaches often applied for antibodies, to project specific strategies. The developability assessment concept applied at Novartis combines information addressing various technical areas, such as expression, aggregation propensity, process fit, stability, physicochemical properties, etc. This integrated concept prior to lead selection provides a thorough, yet resource efficient approach to select suitable candidates.
  • Multiplex immunoassay detection of Alzheimer’s disease biomarkers
    Multiplex immunoassay detection of Alzheimer’s disease biomarkers Anthony Saporita, PhD Recorded: Sep 26 2018 41 mins
    Monitoring protein biomarkers in cerebrospinal fluid (CSF) of patients with Alzheimer’s Disease (AD) has been highly beneficial to understanding disease progression. While several CSF biomarkers can reproducibly distinguish normal and diseased samples, CSF is a difficult biological fluid to obtain in research studies. The need for blood-based biomarkers of AD has driven a continuous search for novel candidates. Here we report the development of a multiplex immunoassay to quantitatively measure seven proteins present in both CSF and blood that are involved in neurological disease: Neurogranin, TREM2, ApoE4, FABP3, Ferritin, angiogenin, and prion protein. Notably, presence of the APOE4 allele is prominently associated with an increased risk for AD, in comparison to the APOE2 and APOE3 alleles. Although these ApoE isoforms differ at only one or two amino acids, our assay distinguished ApoE4 with minimal cross-reactivity. Using this novel immunoassay, we measured these 7 biomarkers in CSF, plasma, and serum from AD patients and healthy controls. Additionally, we developed an ultrasensitive Single Molecule Counting (SMCTM) assay for amyloid beta 1-42 (Aβ42). This kit could detect the Aβ42 peptide in CSF and plasma at sub-pg/mL concentrations. This study demonstrates the value of evaluating both novel and established biomarkers of neurodegeneration across distinct sample types.
  • Tracking technology trends to maximise commercialisation value
    Tracking technology trends to maximise commercialisation value Mireya McKee CEO of McKee Innovation Consulting Recorded: Sep 26 2018 55 mins
    Technology commercialisation at its core requires for an invention to be applied to a use case in a specific market. Doing this successfully will ensure that you are getting ROI out of your research and inventions. Mireya McKee has over 16 years experience in research, academia and commercialisation and will be talking about how she utilises technology trends to maximise commercialisation value.

    Some of the topics discussed in this webinar will be:

    * How to track technology trends
    * What can patents tell us about technology trends
    * Technology adoption cycle
    * How technology readiness levels can affect commercialisation opportunities
  • Machine learning and automation in radiation oncology
    Machine learning and automation in radiation oncology Fredrik Löfman, RaySearch and Tom Purdie, Princess Margaret Cancer Centre Recorded: Sep 26 2018 59 mins
    During the first part of the webinar, Fredrik Löfman, head of machine learning at RaySearch, will discuss how RaySearch is pioneering machine learning for smarter and faster oncology software. He will talk about the upcoming machine-learning applications in RayStation that will be released in December*: automatic treatment planning and automatic organ segmentation. Furthermore, Löfman will discuss some of the other machine-learning projects that RaySearch is working on, such as target-volume delineation, analytics on oncology data and RayCare as a learning system.
    In the second part, Tom Purdie, medical physicist at Princess Margaret Cancer Centre, will talk about automatic treatment planning and machine learning from a clinical perspective. He will present results from a clinical comparison between retrospective plans and ML automated plans.

    * Subject to regulatory clearance in some markets.
  • Understanding and Optimizing Headspace SPME
    Understanding and Optimizing Headspace SPME Robert E. Shirey, Principal R&D Scientist, Merck KGaA, Darmstadt Germany Recorded: Sep 26 2018 59 mins
    Solid phase microextraction (SPME) is a fast, economical, solvent-free, quantitative method for extraction of analytes out of a sample. When analysing volatile and semi-volatile analytes, extraction may be performed in the headspace, or space surrounding the sample, avoiding direct immersion of the fiber. This presentation will provide method development guidance for the extraction and quantification of analytes using headspace SPME. The mechanism of headspace SPME will be explained in detail. Methods for enhancing extraction efficiency will be described. Advantages of headspace SPME over other common extraction methods will be highlighted.
  • Everything you need to know about academic publishing
    Everything you need to know about academic publishing Steven Ward, Editage Academic Trainer Recorded: Sep 26 2018 60 mins
    English is the lingua franca for scholarly communication, and most international journals with a wide global readership are printed in English. Submitting manuscripts in poor English can put researchers at a disadvantage and delay the publication of research. This session will highlight the importance of quality English writing and the need to communicate your research effectively. This session will also focus on understanding journals and the types of manuscripts they publish, so that you can identify the best type of article for your study.
  • Multiplex immunoassay detection of Alzheimer’s disease biomarkers: Session 1
    Multiplex immunoassay detection of Alzheimer’s disease biomarkers: Session 1 Anthony Saporita, PhD Recorded: Sep 26 2018 41 mins
    Monitoring protein biomarkers in cerebrospinal fluid (CSF) of patients with Alzheimer’s Disease (AD) has been highly beneficial to understanding disease progression.  While several CSF biomarkers can reproducibly distinguish normal and diseased samples, CSF is a difficult biological fluid to obtain in research studies.  The need for blood-based biomarkers of AD has driven a continuous search for novel candidates.  Here we report the development of a multiplex immunoassay to quantitatively measure seven proteins present in both CSF and blood that are involved in neurological disease:  Neurogranin, TREM2, ApoE4, FABP3, Ferritin, angiogenin, and prion protein.  Notably, presence of the APOE4 allele is prominently associated with an increased risk for AD, in comparison to the APOE2 and APOE3 alleles.  Although these ApoE isoforms differ at only one or two amino acids, our assay distinguished ApoE4 with minimal cross-reactivity. Using this novel immunoassay, we measured these 7 biomarkers in CSF, plasma, and serum from AD patients and healthy controls.  Additionally, we developed an ultrasensitive Single Molecule Counting (SMCTM) assay for amyloid beta 1-42 (Aβ42).  This kit could detect the Aβ42 peptide in CSF and plasma at sub-pg/mL concentrations.  This study demonstrates the value of evaluating both novel and established biomarkers of neurodegeneration across distinct sample types.
  • Duolink PLA Technology: How to detect and quantify protein interactions
    Duolink PLA Technology: How to detect and quantify protein interactions Cláudia Emanuele, Ph.D. and Paola Braga Recorded: Sep 20 2018 68 mins
    Duolink® proximity ligation assay (PLA) technology allows you to visualize protein interactions with cellular localization and quantities by amplifying signals corresponding to single and post-translational protein events. With 1000x sensitivity and high specificity, this protein detection technology allows to visualize protein functions, all within a native cell. The PLA method provides:
    •Visual protein interactions
    −Both stable and transient
    •Endogenous protein detection
    −No overexpression or genetic manipulation
    •High specificity
    −Use of two antibodies/probes eliminates false positives
    −Single molecule sensitivity
    •Rolling circle amplification makes proteins visible
    •No special equipment needed
    −Standard immunofluorescence methods

    This webinar will review how to work with PLA technology and provide an overview of their potential along with example applications.
  • PD-L1 Assays – More than just an antibody
    PD-L1 Assays – More than just an antibody Dr. Michael Flores Recorded: Sep 18 2018 33 mins
    In this webinar, Dr. Flores will summarize the PD-L1 testing assays currently available on market and address the importance of understanding the different scoring algorithms developed for their respective PD-1/PD-L1 immunotherapies. You will learn about a system approach to testing and where to find further information on how to appropriately interpret the specific PD-L1 assay you are working with.
  • Conquering Aging: Novel Technology Disruptions in the Anti-Aging Industry
    Conquering Aging: Novel Technology Disruptions in the Anti-Aging Industry Frost & Sullivan's Global Transformational Health Experts, Insilico Medicine, ChromaDex, Dthera Sciences Recorded: Sep 18 2018 70 mins
    The anti-aging industry is moving toward a “prevent-manage-repair” continuum that is creating novel market opportunities such as pharmacological targeting of aging, the “drug-as-a-service” business model, the use of digital pills to track drug consumption and adherence, and digital therapies that will help lower costs and reduce side effects.

    Key Takeaways:
    • Discover innovations in anti-aging drugs and therapies, novel nutrition, and digital tools
    • Engage with thought leaders to understand the dynamics around significant market trends, innovative business models, and game-changing companies.
    • Uncover key investment opportunities and growth potential.
  • DSF and FTIR as methods for the identification and characterization
    DSF and FTIR as methods for the identification and characterization Marina Kirkitadze , Deputy Director, Head of Biophysics & Conformation Unit, Analytical R&D Biochemist & Kristen Kalbfleisch Recorded: Sep 18 2018 71 mins
    The focus of this presentation is the application of Fourier Transform Infrared Spectroscopy (FTIR) and Differential Scanning Fluorimetry (DSF) methods to characterize vaccine components and their stability. Additionally, FTIR can be applied for the identification of final vaccine products, and DSF can be used to distinguish different formulations of vaccine candidates. These methods, when used in conjuction, provide valuable information regarding characterization and stability in the final stages of vaccine manufacturing.
  • Advanced process development using automated micro bioreactors shortens timeline
    Advanced process development using automated micro bioreactors shortens timeline Dr. Jincai Li, Vice President and -Liang Tang, PhD, Vice President of WuXi Biologics and Sunil Chhatre, Satorius Stedim Recorded: Sep 14 2018 70 mins
    Presented by Dr. Jincai Li, Vice President of WuXi Biologics and -Liang Tang, PhD, Vice President of WuXi Biologics and Sunil Chhatre, Satorius Stedim Biotec
  • HAXPES measurements in your own laboratory
    HAXPES measurements in your own laboratory Susanna Eriksson, Head of Product Management Electron Spectroscopy Recorded: Sep 13 2018 47 mins
    During the past decade, increased attention has been shown to hard X-rays in the photoelectron spectroscopy (HAXPES) field. This is mainly due to the increased information depth enabled by the higher photon energies. Such bulk sensitive measurements could previously only be performed at dedicated synchrotron radiation facilities. The beam lines providing this type of radiation are heavily booked, so access to the experimental setups is thus limited. Higher excitation energies also enables bulk sensitive measurements of deep core levels not accessible with standard XPS.
    We will present a new system featuring a monochromized X-ray source giving out Ga Ka radiation at 9.25keV and a wide acceptance angle hemispherical electron analyzer, both combined on a simple to use vacuum system. With this system, a new set of possible experiments opens up in the home laboratory: investigations of buried interfaces, in operando devices, real world samples, etc.
  • Next generation processes: What model works the best in Asia?
    Next generation processes: What model works the best in Asia? Ravishankar Kasturi, Reliance Life Sciences & Britta Manser ,Scientist Continuous Bioprocessing Pall Recorded: Sep 11 2018 58 mins
    Next generation processes: What model works the best in Asia?

    Compare and contrast the available full scale processing technologies, and discover what works the best for manufacturing next generation therapeutic products in Asia.

    Biologics are complex and hard to make, which helps to explain why biotech manufacturing plants are huge and expensive to build. To be competitive, manufacturing must be efficient and cost-effective and should brainstorm economical ways to manufacture biologics.

    Biosimilars are a cost competitive market. Pricing may have a direct impact on market share, and return on investment. The market for biologics, including approved and in pipeline like ADCs, antibodies & antibody fragments present both tremendous opportunity and challenge. Challenges necessitates looking beyond the current platform philosophy for how to modify the process with a goal to increase overall productivity in a flexible manner.

    The current processing paradigm of large manufacturing facilities dedicated to single product production is no longer an effective approach for manufacturing next generation therapeutic products in Asia.

    Cost Effective Biosimilars Manufacturing may include
    Single-use technologies and continuous upstream processes have proven to be cost-efficient options
    Aspects of continuous manufacturing in both upstream and downstream manufacturing are being incorporated thereby increasing yields through a combination of longer production run times, more stable and higher secreting cell lines
    Technologies enabling high productivity, right-sized, small footprint, continuous, and automated operations are being evaluated.
    Adaptive control techniques are set to minimize development timelines and enhance process robustness
    Partnerships will continue to transform biosimilars industry. In order to gain access to developed markets, Indian biosimilar manufacturers are partnering with multiple local established manufacturers and big pharmaceutical companies
  • 爱思唯尔卓越科研在线讲座:在《柳叶刀》上发表论文——专为中国研究人员打造的中文在线讲座!
    爱思唯尔卓越科研在线讲座:在《柳叶刀》上发表论文——专为中国研究人员打造的中文在线讲座! Helena Wang Recorded: Sep 6 2018 64 mins
    与《柳叶刀》亚洲区执行主编王辉(Helena Wang)女士一起学习在高影响力期刊上发表论文的技巧和策略。王辉女士将分享她在整个研究论文发表周期中与研究人员和论文作者合作的经验,介绍如何撰写能够在优质出版物上发表的论文,以及广泛传播研究成果的机会。本次在线研讨会内容精彩纷呈,不容错过,能够让您的研究过程和研究影响再上新台阶。This webinar will be in Mandarin (Chinese).
  • 3D Organ-on-a-chip Applications Using the AIM Biotech Chip
    3D Organ-on-a-chip Applications Using the AIM Biotech Chip Kuan Chee Mun and Mahama Aziz Traore Oct 22 2018 1:00 pm UTC 75 mins
    In vitro 3D cell culture models have emerged as a bridge between conventional 2D cell culture models and the complex & expensive in vivo animal models. By analyzing and comparing the biological behavior of tissues embedded in 3 dimensional hydrogels, results are significantly different from classic 2D cell culture in terms of proliferation, morphology, drug response and gene expression. These differences have been attributed to the topographically complex 3D environment surrounding the cells, where cell adhesion, structure, effector transport and mechanotransduction are substantially altered. A carefully designed 3D model can provide more physiologically relevant information using experimental designs unachievable by conventional 2D assays at a fraction of the cost of in vivo models.
    Current 3D cell culture assays like hanging drop culture often lack the capability to organize different co-cultured cell types in a meaningful way. The application of chemical gradients or flow is usually not possible.
    We are now able to address this issue with a modular microfluidic platform that can co-culture multiple cell types in discrete 3D and 2D channels. Organotypic assays with animal model-like complexities using human cells have been developed for research, drug discovery & diagnostics. These include models for immune checkpoint, T-cell killing efficiency, angiogenesis, metastasis, cell migration, microvascular networks and the blood-brain barrier. Additional applications that focus on a liver model will also be discussed. Drug Induced Liver Injuries (DILI) contributes to drug failures, drug withdrawals and acute liver failures. The liver strongly interacts with other organ systems and in some instances the metabolites secreted by the liver are responsible for other organs' injury. Engineered 3D liver models may increase the physiological relevance of drug toxicity by maintaining the expression levels of key cytochrome P450 enzymes and metabolic activity in liver cells.
  • Making new connections – An overview of new TLC-MS Applications Session 1
    Making new connections – An overview of new TLC-MS Applications Session 1 Michaela Oberle Oct 23 2018 7:00 am UTC 75 mins
    In the last decade the trend for hyphenating different analytical techniques became an more and more important role in analytical labs. Combinations like LC-LC-MS or LC-MS-MS help to solve the analysis of complex samples in a proper way. The Analytical data which could be received are more sensitive focused on special analytes or give a better overview of the whole sample composition.

    This webinar should give the attendances an overview of the advantage and strength of (HP)TLC- MS coupling technique along various Applications from different analytical fields using different MS techniques. Tips and tricks for the right handling are be presented, to avoid main basic defaults.
  • Making new connections – An overview of new TLC-MS Applications Session 2
    Making new connections – An overview of new TLC-MS Applications Session 2 Michaela Oberle Oct 23 2018 2:00 pm UTC 75 mins
    In the last decade the trend for hyphenating different analytical techniques became an more and more important role in analytical labs. Combinations like LC-LC-MS or LC-MS-MS help to solve the analysis of complex samples in a proper way. The Analytical data which could be received are more sensitive focused on special analytes or give a better overview of the whole sample composition.

    This webinar should give the attendances an overview of the advantage and strength of (HP)TLC- MS coupling technique along various Applications from different analytical fields using different MS techniques. Tips and tricks for the right handling are be presented, to avoid main basic defaults.
  • AU Analyzer Advanced Troubleshooting
    AU Analyzer Advanced Troubleshooting Lisa Hammett, Chemistry Product Manager, Beckman Coulter Oct 24 2018 6:00 pm UTC 90 mins
    In the AU Analyzer Advanced Troubleshooting webinar, the Reliability Improvement Team shares advanced troubleshooting techniques that can help laboratories ensure uptime and reliability of their AU chemistry analyzers. The helpful tools presented during this webinar are based on customer feedback gathered from technical support calls and field service support visits with technologists using our AU systems.

    The presentation is designed to provide you with useful practices and troubleshooting tips for maximum AU analyzer reliability and uptime. This includes an overview of:

    • Common items that can impact results
    • Key analyzer functions, reaction sequence and data calculation
    • Problem-solving techniques for optical density check flags
    • Troubleshooting methods for photocal and other errors

    P.A.C.E. credit and State of Florida CEUs are available for your participation.*

    About the speaker:
    Lisa Hammett holds a B.S. degree in medical technology from the University of Texas at Austin. For almost a decade, Lisa has served as a senior analyst in chemistry product management marketing with Beckman Coulter, specializing in AU chemistry systems. Prior to Beckman Coulter, Lisa served for 16 years as a course developer and customer trainer for AU analyzers with Olympus.

    *Beckman Coulter Inc. is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. These credits are recognized by the State of California. Most programs also provide State of Florida credits (with valid license number). At this time, we cannot issue continuing education credits for those who provide healthcare (or work for an institution that provides healthcare) in Massachusetts or Vermont.
  • Emerging Quantum Dot Materials: Synthesis and Application
    Emerging Quantum Dot Materials: Synthesis and Application Osman M. Bakr, PhD Oct 25 2018 1:00 pm UTC 75 mins
    Quantum Dots (QDs) undoubtedly attracted lots of interest with their superior luminescent properties. What is distinct about their luminescent properties is that the wavelengths of emitted light can be precisely tuned by changing of nanoparticle size or composition. Quantum dots possess narrow full width at half maximum (FWHM), high photoluminescence quantum yield (PLQY), emission wavelength tunability through the entire visible and near IR range. In this webinar, we talk about synthesis and application of emerging quantum dots materials: Perovskite and PbS QDs. Perovskite QDs emit light within the visible range, have high PLQY (up to 100 %), narrow FWHM (below 20-25 nm), and are considered as the best alternatives for CdSe and InP QDs for display application. PbS QDs emit light in near IR region with narrow FWHM of absorption and emission, making them ideal in NIR photodetectors and solar cells.
  • Safety First Throughout the Histology Workflow
    Safety First Throughout the Histology Workflow Shalmica Jackson, PhD Oct 25 2018 4:00 pm UTC 75 mins
    From tissue processing to slide coverslipping, the histology workflow is laden with hazardous steps. Chemical sensitizers, strong acids, alkaline substances, and oxidizing agents are routinely used during histological workflows. These classes of chemicals are known to damage and even destroy living tissues. Ensuring the safety of laboratory workers is of the utmost importance. This workshop will present new approaches to help make the histopathology laboratory a safer environment with the use of formalin-free fixatives, phenol-free stains, DBP-free mounting media, IVD-certified ready-to-use reagents, and more.
  • High Precision PCR utilizing ThermaGenix Reagents
    High Precision PCR utilizing ThermaGenix Reagents Professor Lawrence Wangh, Founder and CSO of ThermaGenix, Inc. Oct 30 2018 3:00 pm UTC 60 mins
    The polymerase chain reaction (PCR) is a mainstay of molecular biology and genomics that provides an efficient and rapid in vitro method for enzymatic amplification of DNA or RNA sequences from various sources. There are three unique, easy-to-use PCR additives that act at different temperatures to improve sensitivity and product yield by preventing mis-priming:

    1. ThermaStop™: a novel reagent that acts like a universal hot-start for Type A and Type B DNA polymerases
    2. ThermaGo™: a unique reagent that enhances the specificity of these same enzymes during the course of amplification
    3. ThermaStop™-RT: a first-in-class reagent that acts like a hot-start for many reverse transcriptases.

    Each reagent is a chemically modified oligonucleotide produced under GMP conditions and sold as a dry powder. Stable at room temperature, each reagent can simply be added to the enzyme of your choice prior to adding that enzyme/reagent complex to the master mix. These improvements are observed for both inexpensive Type A Taq polymerases and very expensive HiFi Type B DNA polymerases in applications such as qPCR, multiplexing, and preparation of DNA amplicons prior to next-generation sequencing (NGS).
  • Get off Your Lazy NAS by Transforming Your Data Management Strategy
    Get off Your Lazy NAS by Transforming Your Data Management Strategy Stefaan Vervaet, Sr. Director, DCS Solutions & Alliances, Western Digital; Krishna Subramanian, COO, Komprise Oct 30 2018 5:00 pm UTC 30 mins
    NAS is essential to your IT environment, but a lazy NAS can hurt performance, cause you extra work and bust your budget.

    Join experts from Western Digital and Komprise to learn how to transform your data management strategy by gaining visibility and an understanding of your data, automating the movement of inactive data to less expensive storage and optimizing your storage environment.

    In this webinar you’ll learn how to:
    •Increase NAS performance
    •Free up NAS capacity
    •Reduce costs by up to 50% or more
    •Reduce backup times by up to 60 percent or more

    A small investment of time can deliver BIG cost savings!
  • Medical Marijuana Market Trends—Future Clinical Role of Medical Marijuana & CBD
    Medical Marijuana Market Trends—Future Clinical Role of Medical Marijuana & CBD Nitin Naik (Moderator) Barbara Gilmore, Senior Consultant, Frost & Sullivan, Dr. Joseph C. Maroon, University of Pittsburgh Oct 30 2018 8:00 pm UTC 75 mins
    Medical cannabis use is driving industry revenues into the billions. Investments by pharmaceutical and Big Tobacco companies in the development of cannabis and CBD-based products and devices, along with healthcare-conscious consumers having access to these products, are spurring growth. Physicians, aware of increasingly widespread medical marijuana legalization, are interested in understanding the potential of these treatments. In US states where cannabis is approved, the use of prescription drugs, including the use of opioids, has decreased.

    Key Takeaways:
    • Learn about a variety of medical marijuana science and clinical uses/applications (patient experiences)
    • Discover health-related applications of medical marijuana based on interactions with the endocannabinoid system
    • Explore the latest clinical research in cancer, neurological, psychological, metabolic and pain disorders using medical marijuana
  • How to accelerate FTO searches on sequences by 70%
    How to accelerate FTO searches on sequences by 70% Jessie Parker @ PatSnap Oct 31 2018 4:00 pm UTC 60 mins
    Scientists in the biotech and pharma industries spend a large amount of time and resources on researching sequences. However, often as researches progress to the later stages of R&D, they become blocked by competitors and products that are already on the market.

    Using a sequence searching tool which links to patent data can help you identify obstacles and freedom to operate much earlier on. Having access to a full data set sooner, can help you save time, money and enhance your R&D.

    Join this webinar to find out how you can accelerate FTO searches on your sequences.
  • Advances and Challenges in Vaccine Development and Manufacture
    Advances and Challenges in Vaccine Development and Manufacture Tony D’Amore, Sanofi Pasteur Nov 2 2018 2:00 pm UTC 75 mins
    This webinar reviews the constraints and complexities of vaccine product development and manufacture.
    The evolution of bioprocess and analytics innovation and technologies to overcome these challenges are discussed.
    The strategy and leveraging of innovation and technology for rapid product development and accelerating timelines is described.
    Case studies to illustrate the advances in vaccine development and manufacture are illustrated.
    A look into the future with state of the art technologies.
  • Beyond the Blame Game: Improving Patient, Physician, Pharma Relation
    Beyond the Blame Game: Improving Patient, Physician, Pharma Relation Andrew McConaghie Nov 7 2018 3:00 pm UTC 60 mins
    We often hear patients report a lack of ‘connection’ with their physician, and where lifestyle plays a role in the development of a disease, such as obesity or type 2 diabetes, patients may even feel the doctor blames them for their condition.

    So how can patients and healthcare professionals move beyond the ‘blame game’? This webinar will explore:
    • How HCPs and patients can establish a better partnership
    • The role pharma can play in facilitating this change
    • Opportunities for intervention at key points in the patient journey

    Join Cello Health Insight and Pharmaceutical Market Europe (PME)’s webinar to hear an expert discussion of these issues and the consequences for the patient, the patient-physician relationship and for pharma.
  • Protein Sample Prep Tips & Tricks
    Protein Sample Prep Tips & Tricks Natasha L. Pirman, Ph.D. Nov 7 2018 4:00 pm UTC 75 mins
    E. coli is the most widely used recombinant expression system to overexpress protein given that it is inexpensive, easy to scale up, and relatively fast. Due to its wide-spread use, there are numerous molecular tools, products, and expression/purification protocols available. Determining which tools and products to use, such as plasmid, strain-type, affinity tag and resin system, or buffer exchange device can be daunting. Here, we present a workflow overview of the recombinant protein expression from E. coli and provide insight and various tips and tricks about how to optimize and improve protein yield and purity enabling you to make the best decisions for your protein of interest.
  • Regulatory Approval of Three Rapid Microbiological Methods for MACI Product Rele
    Regulatory Approval of Three Rapid Microbiological Methods for MACI Product Rele John Duguid, Senior Director, at Vericel Corporation in Cambridge, and Nicola Reid, Senior Product Manager at Charles River Nov 8 2018 3:00 pm UTC 75 mins
    Title:Regulatory Approval of Three Rapid Microbiological Methods for MACI Product Release

    Rapid detection of contaminants is essential for cell therapy products with short shelf lives. Integrating quality into the process through lot segregation, raw material qualification, environmental control, personnel training, and detailed procedures is critical because final results for conventional microbiological tests may not be available prior to product release or patient administration. EMA approval of the MACI MAA in 2013 followed by US FDA BLA approval in 2016 included three RMM product release assays for sterility, endotoxin, and mycoplasma.
  • 2019 Healthcare Predictions – Growth Opportunities, Technology, and Trends
    2019 Healthcare Predictions – Growth Opportunities, Technology, and Trends Reenita Das, Partner and Senior Vice President, Kamaljit Behera, Industry Analyst, Transformational Healthcare Nov 8 2018 6:00 pm UTC 75 mins
    During 2019, digital health will start to come of age. Favorable reimbursement policies toward clinically relevant digital health applications will expand care delivery models beyond physical medicine to include behavioral health, digital wellness therapies, dentistry, nutrition, and prescription management. Innovative digital patient engagement platforms capable of capturing tailored information on lifestyle and behavioral-based health risks data will have a white space opportunity to provide patient risk classification solutions to make precision health a holistic approach.

    Key Takeaways:
    • Learn how the convergence of cutting-edge technology such as artificial intelligence, big data, cloud, and blockchain will help shape the healthcare industry into a much anticipated, value-based care paradigm.
    • Identify new opportunities connected to the pharmaceutical, biotechnology, medical technologies, diagnostics, medical imaging, and healthcare IT sectors.
    • Understand which investments will pay off regarding productivity, efficiency and better outcomes for patients in 2019 and beyond.
  • Cell Culture in 3D Systems; Moving from a 2D to 3D Environment
    Cell Culture in 3D Systems; Moving from a 2D to 3D Environment Seth Hanson, Academic Research Technology Specialist - Merck KGaA, Darmstadt, Germany Nov 9 2018 2:00 am UTC 75 mins
    Cell culture in 3D systems: moving from 2D to 3D cell culture?
    It’s now well accepted by the scientific community that the 3D cell culture condition better recapitulate the in vivo environment and behaviours of cells. But it’s not a trivial change to move from 2D cell culture conditions to 3D, and not always easy to choose the right system to use.

    An understanding of the key parameters for 2D and 3D cell culture will be reviewed, followed by an overview of the technologies available at Merck with features, benefits, and application data.
  • Efficiency by Design- Case Study for a Hybrid Clinical Manufacturing Facility
    Efficiency by Design- Case Study for a Hybrid Clinical Manufacturing Facility Dr Sourav Kundu, Senior Director at Teva Pharmaceuticals Global Biologics R&D and Adam Kaletski, Business Leader, Bioprocess Nov 9 2018 3:00 pm UTC 75 mins
    · Facility needs and characteristics for clinical manufacturing
    · Single-use or stainless steel?
    · When to use single-use equipment
    · Hybrid manufacturing facilities – best of both worlds
    · Teva’s clinical manufacturing facility – attributes, layout, construction, qualification, choice of equipment
    · Final thoughts
  • Mixed mode Chromatography in Purifying biologics - Overview
    Mixed mode Chromatography in Purifying biologics - Overview Vivek Halan Zumutor Biologics Pvt Ltd, Bangalore, India Nov 15 2018 9:30 am UTC 75 mins
    This Webinar will discuss MMC in purifying biologics which includes monoclonal antibodies (mAbs), Bispecific antibodies (BsAbs), antibody fragments (Scfv,Fab) and other recombinant proåteins. My discussion is intended for audience from biopharmaceutical industry as well as active collaborators from academic institutes.
  • More Success in LC-MS: Tips and Tricks for Sample & Mobile Phase Preparation and
    More Success in LC-MS: Tips and Tricks for Sample & Mobile Phase Preparation and Vivek Joshi, PhD Nov 15 2018 4:00 pm UTC 75 mins
    LC-MS is one of the most commonly used analytical techniques in various sectors for quantitation and identification of unknown from variety of complex samples. Use of LC-MS has expanded over the years as it offers both selectivity and specificity in analysis. With advances in both chromatography and mass spectrometry, sensitivity and accuracy of this technique has further increased, allowing for detection and identification of low-level analytes in complex sample matrices.

    The LC-MS workflow has three main components, which determine successful analyses: sample preparation, choice of mobile phase components and column selection. Not paying enough attention to one of these components can complicate data analysis, quantitation and identification.

    In this seminar, you will learn critical factors to consider when selecting the sample preparation methods, mobile phase components and HPLC columns.
  • Accelerating Discovery with In Situ Electron Microscopy
    Accelerating Discovery with In Situ Electron Microscopy Jordan Moering, Protochips and Ray Unocic, Oak Ridge National Lab Nov 15 2018 4:00 pm UTC 60 mins
    As the imaging and analytical capabilities of the modern transmission electron microscope (TEM) have improved, it has become an increasingly vital tool to characterize and study nanoscale materials. With the advent of MEMS-based sample supports, researchers are now capable of easily heating and electrically characterizing their sample in situ, directly imaging the dynamic sample reactions occurring at the atomic scale.

    For semiconductor and electrical device applications, Protochips has developed focused ion beam (FIB) tools and sample preparation workflows that enable researchers to prepare FIB lamellae directly on MEMS-based sample supports, allowing pA-level electrical characterization of their sample at atomic resolution. With the growing interest surrounding graphene and other 2D materials, in situ TEM has become increasingly utilized to accelerate the discovery of these next-generation materials. At Oak Ridge National Laboratory, researchers Xiahan Sang and Ray Unocic used in situ heating to synthesize and characterize complex structural and chemical transformations of edge defects at atomic resolution. Their work pioneered new means by which 2D materials could be engineered directly in the TEM, opening new avenues for materials development and characterization. These and other novel results in the field of material science will be presented in this webinar.
  • Evolve Manufacturing Processes by Implementing Disruptive Technologies
    Evolve Manufacturing Processes by Implementing Disruptive Technologies Yuyi Shen PhD, Principal Scientist, Grifols, John Cyganowski, Director of Manufacturing Sciences and Technologies Downstream Nov 19 2018 5:00 pm UTC 75 mins
    The desire for innovative technology that can eventually cause disruptive improvement remains high in the biotech pharmaceutical industry. The road between pursuing and developing that technology to genuine implementing is not a smooth ride. In this webinar, the presenter identifies key challenges of implementing innovative technologies and the major drive for implementing innovative technologies and process upgrades. The presenter will share some case studies of implementing successful innovation tools and provide comparative economic analysis based on the understanding the true value of innovation driven process design. The webinar also provide the insight of the balance needs for quality, cost and speed.
  • How to get published in Austria
    How to get published in Austria Jane Hesling, Associate Editor, IOP Publishing Nov 20 2018 9:30 am UTC 60 mins
    The webinar, aimed at early career researchers, will cover a range of topics including how to choose the right journal, peer-review and publication ethics, and your open access publishing options thanks to funding agreements in Austria.
  • Expert Tips for Publishing in JACC Journals and Cardiovascular Health Promotion
    Expert Tips for Publishing in JACC Journals and Cardiovascular Health Promotion Dr. Valentin Fuster, M.D., Ph.D. Nov 29 2018 2:30 pm UTC 105 mins
    Join Valentin Fuster, MD, PhD, MACC, editor-in-chief of the Journal of the American College of Cardiology (JACC) to learn techniques and strategies for publishing in high-impact journals. During this engaging webinar intended for new and experienced researchers, Dr. Fuster will share his expertise in working with researchers and authors throughout the research publishing cycle; uncover strategies for developing papers for premium publications; and discuss the opportunities journals present to broadly disseminate findings. Evidence of the potential reach and impact of published research, Dr. Fuster will also present on the recent JACC Cardiovascular Health Promotion Series and how preventing cardiovascular disease is as important as treating it. Don’t miss this engaging webinar and how it can benefit your authoring process and the impact of your research.
  • Next Generation IHC
    Next Generation IHC Jeff Gordon Dec 5 2018 4:00 pm UTC 75 mins
    Immunohistochemistry has now been a staple in diagnostic pathology for decades. This is partially due to pathologist utilization of antibodies in the realm of specialty panels. As the science evolves, the panels evolve, creating demand for the next generation of antibodies to improve diagnostic capabilities. This talk will give an overview of some of these novel diagnostic markers and how they fit into the specialty panels with the traditional antibodies to provide the best diagnostic capabilities to the pathologist, therefore giving the patient the best care available.
  • Overview of Certification Procedures for Organic Certified Reference Materials
    Overview of Certification Procedures for Organic Certified Reference Materials Ingrid Hayenga, PhD & Markus Obkircher, PhD Dec 12 2018 7:00 am UTC 75 mins
    his webinar highlights the different certification procedures regarding organic standards.

    Certified reference materials (CRMs) are an important and essential part of quality assurance. Laboratories accredited according to ISO 17025 must use CRMs on a regular base to prove their quality.

    For organic compounds, only a very limited number of CRMs from metrological institutes are available, due to this the big challenge is traceability.


    In this webinar, you will learn:
    •The certification process of the organic standard solutions by qNMR from the point of view of a commercial producer of certified reference materials under ISO/IEC 17025 and ISO 17034 accreditation.